This site uses no trackers, cookies, and no data is collected from visitors of this site.
Trypt.am is a shortening for the word *tryptamine*.
info (at) entheos (dot) org (dot) nz
To see complete record on anzctr.org.au, please visit this link
Organisation Name: University of Otago
Overal Status: Not yet recruiting
Start Date: 01/06/2020
Brief Summary: EMMAC is a randomised controlled trial studying the effects of MDMA-assisted therapy on mood and anxiety symptoms in advanced-stage cancer patients. Standard dose MDMA (120mg + optional 60mg) will be compared to a psychoactive placebo (Methylphenidate 20mg + optional 10mg) with both being given as a single dose. On the basis of MDMA pharmacology and recent research showing promising results with the use of psilocybin to reduce anxiety and depression in patients with advanced-stage cancer (Grob et al., 2011, Griffiths et al., 2016, Ross et al., 2016) we hypothesise that MDMA may have the potential to achieve similar positive mental health outcomes with reduced psychological risk given the differences in psychopharmacological effects.Countries: